About Cambrex Corporation (NYSE:CBM)
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc., Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l. Its products consist of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. It delivers services, such as custom organic synthesis and process development; current good manufacturing practices (cGMP) manufacturing of API and intermediates from grams to hundreds of kilograms; cGMP analytical services; controlled substance research and development (R&D) and manufacture, Schedule II-V, and contract research. It has API R&D and cGMP facilities in the United States and Europe. It supplies over 90 generic APIs.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals
- Sub-Industry: Life Sciences Tools & Services
- Symbol: NYSE:CBM
- CUSIP: 13201110
- Web: www.cambrex.com
- Market Cap: $1.72 billion
- Outstanding Shares: 32,729,000
- 50 Day Moving Avg: $53.33
- 200 Day Moving Avg: $55.45
- 52 Week Range: $38.30 - $62.95
Sales & Book Value:
- Trailing P/E Ratio: 19.14
- Foreward P/E Ratio: 16.53
- P/E Growth: 1.14
- Annual Revenue: $515.45 million
- Price / Sales: 3.34
- Book Value: $14.38 per share
- Price / Book: 3.65
- EBITDA: $167.23 million
- Net Margins: 17.70%
- Return on Equity: 24.25%
- Return on Assets: 16.45%
- Current Ratio: 4.15%
- Quick Ratio: 2.37%
- Average Volume: 310,391 shs.
- Beta: 2.28
- Short Ratio: 9.07
Frequently Asked Questions for Cambrex Corporation (NYSE:CBM)
What is Cambrex Corporation's stock symbol?
Cambrex Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."
How were Cambrex Corporation's earnings last quarter?
Cambrex Corporation (NYSE:CBM) released its quarterly earnings results on Friday, August, 4th. The company reported $0.76 earnings per share for the quarter, meeting analysts' consensus estimates of $0.76. The company had revenue of $134.55 million for the quarter, compared to analyst estimates of $136.82 million. Cambrex Corporation had a net margin of 17.70% and a return on equity of 24.25%. The firm's revenue was up 13.4% on a year-over-year basis. During the same period last year, the firm earned $0.68 earnings per share. View Cambrex Corporation's Earnings History.
When will Cambrex Corporation make its next earnings announcement?
What guidance has Cambrex Corporation issued on next quarter's earnings?
Cambrex Corporation issued an update on its FY17 earnings guidance on Friday, August, 4th. The company provided earnings per share (EPS) guidance of $3.00-3.12 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.03. The company issued revenue guidance of $525-545 million (+7-11%), compared to the consensus revenue estimate of $536.87 million.
Where is Cambrex Corporation's stock going? Where will Cambrex Corporation's stock price be in 2017?
3 brokerages have issued twelve-month price objectives for Cambrex Corporation's stock. Their forecasts range from $61.00 to $70.00. On average, they expect Cambrex Corporation's share price to reach $65.67 in the next year. View Analyst Ratings for Cambrex Corporation.
Who are some of Cambrex Corporation's key competitors?
Some companies that are related to Cambrex Corporation include BTG plc (BTG), Hikma Pharmaceuticals Plc (HIK), Horizon Pharma PLC (HZNP), Amicus Therapeutics (FOLD), Corcept Therapeutics Incorporated (CORT), Theravance Biopharma (TBPH), Emergent Biosolutions (EBS), Impax Laboratories (IPXL), Innoviva (INVA), Pacira Pharmaceuticals (PCRX), Akcea Therapeutics (AKCA), Lannett Co (LCI), Amphastar Pharmaceuticals (AMPH), SciClone Pharmaceuticals (SCLN), AMAG Pharmaceuticals (AMAG), Corium International (CORI), Collegium Pharmaceutical (COLL) and Teligent (TLGT).
Who are Cambrex Corporation's key executives?
Cambrex Corporation's management team includes the folowing people:
- Steven Mark Klosk, President, Chief Executive Officer, Director
- Tom George Vadaketh, Chief Financial Officer, Executive Vice President
- Shawn P. Cavanagh, Chief Operating Officer, Executive Vice President
- Gregory P. Sargen, Executive Vice President, Corporate Development and Strategy
- Samantha M. Hanley, Vice President, General Counsel,Corporate Secretary
- James G. Farrell, Vice President and Corporate Controller
- Shlomo Yanai, Non-Executive Chairman of the Board
- Rosina B. Dixon M.D., Independent Director
- Claes Glassell, Independent Director
- Louis J. Grabowsky, Independent Director
Who owns Cambrex Corporation stock?
Cambrex Corporation's stock is owned by many different of retail and institutional investors. Top institutional investors include Tributary Capital Management LLC (0.71%), Eqis Capital Management Inc. (0.23%) and Beacon Financial Group (0.02%). Company insiders that own Cambrex Corporation stock include Gregory Sargen, Ilan Kaufthal, Leon J Hendrix Jr, Leon J Hendrix, Jr, Louis J Grabowsky, Peter G Tombros, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and William B Korb. View Institutional Ownership Trends for Cambrex Corporation.
Who sold Cambrex Corporation stock? Who is selling Cambrex Corporation stock?
Cambrex Corporation's stock was sold by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc. and Beacon Financial Group. Company insiders that have sold Cambrex Corporation stock in the last year include Gregory Sargen, Leon J Hendrix Jr, Samantha Hanley, Shawn Cavanagh and Steven M Klosk. View Insider Buying and Selling for Cambrex Corporation.
Who bought Cambrex Corporation stock? Who is buying Cambrex Corporation stock?
How do I buy Cambrex Corporation stock?
Shares of Cambrex Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cambrex Corporation's stock price today?
MarketBeat Community Rating for Cambrex Corporation (NYSE CBM)MarketBeat's community ratings are surveys of what our community members think about Cambrex Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Cambrex Corporation stock can currently be purchased for approximately $52.55.
Earnings History for Cambrex Corporation (NYSE:CBM)Earnings History by Quarter for Cambrex Corporation (NYSE CBM)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/4/2017||Q2 2017||$0.76||$0.76||$136.82 million||$134.55 million||View||N/A|
|5/4/2017||Q1 2017||$0.51||$0.68||$99.05 million||$105.01 million||View||Listen|
|2/3/2017||Q416||$1.05||$1.23||$174.53 million||$178.70 million||View||Listen|
|11/4/2016||Q3||$0.41||$0.47||$96.07 million||$99.90 million||View||Listen|
|7/28/2016||Q216||$0.59||$0.68||$114.85 million||$118.22 million||View||Listen|
|4/29/2016||Q116||$0.34||$0.50||$83.61 million||$94.74 million||View||Listen|
|2/9/2016||Q4||$0.83||$0.53||$152.94 million||$156.90 million||View||Listen|
|11/3/2015||Q3||$0.38||$0.40||$101.09 million||$92.97 million||View||Listen|
|7/30/2015||Q215||$0.44||$0.63||$110.03 million||$106.40 million||View||Listen|
|5/1/2015||Q115||$0.23||$0.29||$76.01 million||$78.20 million||View||Listen|
|2/6/2015||Q414||$0.50||$0.60||$117.90 million||$128.80 million||View||Listen|
|10/30/2014||Q314||$0.29||$0.28||$94.25 million||$81.10 million||View||Listen|
|8/1/2014||Q214||$0.28||$0.32||$92.70 million||$98.00 million||View||Listen|
|5/2/2014||Q114||$0.23||$0.05||$79.40 million||$66.20 million||View||Listen|
|2/11/2014||Q4||$0.30||$0.30||$95.25 million||$103.00 million||View||Listen|
|11/1/2013||Q313||$0.21||$0.20||$83.60 million||$78.00 million||View||Listen|
|8/1/2013||Q2 2013||$0.26||$0.10||$73.70 million||$61.60 million||View||Listen|
|5/3/2013||Q1 2013||$0.22||$0.36||$76.15 million||$74.58 million||View||Listen|
|2/6/2013||Q4 2012||$0.13||$0.26||$68.30 million||$69.93 million||View||Listen|
|11/5/2012||Q312||$0.12||$0.07||$61.00 million||$59.21 million||View||N/A|
Earnings Estimates for Cambrex Corporation (NYSE:CBM)
2017 EPS Consensus Estimate: $2.91
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Cambrex Corporation (NYSE:CBM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Cambrex Corporation (NYSE:CBM)
Insider Ownership Percentage: 2.48%Insider Trades by Quarter for Cambrex Corporation (NYSE:CBM)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/2/2017||Steven M Klosk||CEO||Sell||4,000||$54.96||$219,840.00|| |
|9/1/2017||Steven M Klosk||CEO||Sell||12,000||$51.53||$618,360.00|| |
|8/1/2017||Steven M Klosk||CEO||Sell||12,000||$61.39||$736,680.00|| |
|7/3/2017||Steven M Klosk||CEO||Sell||12,000||$59.66||$715,920.00|| |
|6/12/2017||Samantha Hanley||VP||Sell||14,000||$57.56||$805,840.00|| |
|6/6/2017||Leon J Hendrix Jr||Director||Sell||20,656||$55.95||$1,155,703.20|| |
|6/1/2017||Steven M Klosk||CEO||Sell||12,000||$54.19||$650,280.00|| |
|5/1/2017||Steven M Klosk||CEO||Sell||12,000||$58.20||$698,400.00|| |
|4/3/2017||Steven M Klosk||CEO||Sell||12,000||$54.58||$654,960.00|| |
|3/1/2017||Steven M Klosk||CEO||Sell||12,000||$56.70||$680,400.00|| |
|2/27/2017||Shawn Cavanagh||COO||Sell||19,620||$55.95||$1,097,739.00|| |
|2/16/2017||Steven M Klosk||CEO||Sell||23,822||$52.50||$1,250,655.00|| |
|2/13/2017||Steven M Klosk||CEO||Sell||63,178||$52.55||$3,320,003.90|| |
|2/7/2017||Gregory Sargen||EVP||Sell||30,000||$54.88||$1,646,400.00|| |
|2/7/2017||Shawn Cavanagh||COO||Sell||20,380||$55.12||$1,123,345.60|| |
|12/14/2016||Shawn Cavanagh||COO||Sell||30,000||$53.58||$1,607,400.00|| |
|11/11/2016||Gregory Sargen||Insider||Sell||22,500||$52.02||$1,170,450.00|| |
|7/11/2016||William B Korb||Director||Sell||3,420||$55.00||$188,100.00|| |
|6/8/2016||William B Korb||Director||Sell||4,142||$52.47||$217,330.74|| |
|6/1/2016||William B Korb||Director||Sell||8,000||$51.06||$408,480.00|| |
|5/9/2016||Steven M Klosk||CEO||Sell||14,005||$49.00||$686,245.00|| |
|5/5/2016||Steven M Klosk||CEO||Sell||16,430||$49.13||$807,205.90|| |
|5/3/2016||William B Korb||Director||Sell||8,000||$49.09||$392,720.00|| |
|3/16/2016||Steven M Klosk||CEO||Sell||19,565||$41.00||$802,165.00|| |
|3/15/2016||Louis J Grabowsky||Director||Buy||750||$40.10||$30,075.00|| |
|3/10/2016||William B Korb||Director||Sell||8,000||$41.38||$331,040.00|| |
|2/11/2016||Gregory Sargen||CFO||Sell||13,622||$36.16||$492,571.52|| |
|2/11/2016||Shawn Cavanagh||COO||Sell||18,342||$36.13||$662,696.46|| |
|2/11/2016||Steven M. Klosk||CEO||Sell||39,542||$36.20||$1,431,420.40|| |
|12/15/2015||Leon J. Hendrix, Jr.||Director||Sell||7,000||$51.34||$359,380.00|| |
|12/11/2015||Peter G. Tombros||Director||Sell||31,236||$51.37||$1,604,593.32|| |
|11/30/2015||Ilan Kaufthal||Director||Sell||52,315||$54.32||$2,841,750.80|| |
|11/13/2015||Gregory Sargen||CFO||Sell||28,750||$49.14||$1,412,775.00|| |
|11/6/2015||Samantha Hanley||VP||Sell||15,000||$52.03||$780,450.00|| |
|8/27/2015||William B. Korb||Director||Sell||3,600||$48.00||$172,800.00|| |
|5/21/2015||Ilan Kaufthal||Director||Sell||50,000||$41.31||$2,065,500.00|| |
|5/11/2015||Gregory Sargen||CFO||Sell||25,000||$38.44||$961,000.00|| |
|2/12/2015||Aldo Magnini||Director||Sell||7,500||$32.75||$245,625.00|| |
|2/12/2015||Gregory Sargen||CFO||Sell||25,000||$32.64||$816,000.00|| |
|2/10/2015||Steven M Klosk||CEO||Sell||45,000||$30.32||$1,364,400.00|| |
|9/11/2014||Shawn Cavanagh||COO||Sell||56,251||$22.56||$1,269,022.56|| |
|9/3/2014||Steven M Klosk||CEO||Sell||126,257||$22.01||$2,778,916.57|| |
|9/2/2014||William M Haskel||SVP||Sell||9,400||$21.94||$206,236.00|| |
|8/19/2014||Steven M Klosk||CEO||Sell||4,702||$22.00||$103,444.00|| |
|8/7/2014||Steven M Klosk||CEO||Sell||1,200||$22.52||$27,024.00|| |
|8/7/2014||William M Haskel||SVP||Sell||28,100||$22.50||$632,250.00|| |
|8/5/2014||Gregory Sargen||CFO||Sell||50,000||$22.34||$1,117,000.00|| |
|2/28/2014||Leon Hendrix, Jr.||Director||Sell||23,000||$20.09||$462,070.00|| |
|2/20/2014||Aldo Magnini||Director||Sell||6,000||$22.10||$132,600.00|| |
|12/5/2013||Paolo Russolo||Insider||Sell||35,000||$18.40||$644,000.00|| |
|11/11/2013||Gregory Sargen||CFO||Sell||20,000||$18.92||$378,400.00|| |
|11/11/2013||John Miller||Director||Sell||2,000||$19.21||$38,420.00|| |
|5/24/2013||Paolo Russolo||Insider||Sell||32,903||$12.53||$412,274.59|| |
|5/16/2013||Leon J Hendrix Jr||Director||Sell||1,120||$13.40||$15,008.00|| |
Headline Trends for Cambrex Corporation (NYSE:CBM)
Latest Headlines for Cambrex Corporation (NYSE:CBM)
Loading headlines, please wait.
Cambrex Corporation (CBM) Chart for Sunday, October, 22, 2017